DZ2805A1 - Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages. - Google Patents

Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages.

Info

Publication number
DZ2805A1
DZ2805A1 DZ990105A DZ990105A DZ2805A1 DZ 2805 A1 DZ2805 A1 DZ 2805A1 DZ 990105 A DZ990105 A DZ 990105A DZ 990105 A DZ990105 A DZ 990105A DZ 2805 A1 DZ2805 A1 DZ 2805A1
Authority
DZ
Algeria
Prior art keywords
pyrimidine
pyrrolo
compositions
pyrimidine compositions
Prior art date
Application number
DZ990105A
Other languages
English (en)
Inventor
Arlindo L Casteihano
David J Witter
Bryan Mckibben
Original Assignee
Cadus Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadus Pharmaceutical Corp filed Critical Cadus Pharmaceutical Corp
Application granted granted Critical
Publication of DZ2805A1 publication Critical patent/DZ2805A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DZ990105A 1998-06-02 1999-06-01 Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages. DZ2805A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8770298P 1998-06-02 1998-06-02
US12321699P 1999-03-08 1999-03-08
US12652799P 1999-03-26 1999-03-26

Publications (1)

Publication Number Publication Date
DZ2805A1 true DZ2805A1 (fr) 2005-01-30

Family

ID=27375739

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990105A DZ2805A1 (fr) 1998-06-02 1999-06-01 Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages.

Country Status (25)

Country Link
US (3) US6800633B2 (fr)
EP (2) EP2011499A3 (fr)
JP (1) JP4611524B2 (fr)
KR (1) KR100722194B1 (fr)
CN (1) CN100528874C (fr)
AP (1) AP1411A (fr)
AR (1) AR020590A1 (fr)
AU (1) AU763658B2 (fr)
BR (1) BR9911612A (fr)
CA (1) CA2334200C (fr)
CZ (1) CZ302486B6 (fr)
DZ (1) DZ2805A1 (fr)
EA (1) EA003604B1 (fr)
HU (1) HUP0103836A3 (fr)
ID (1) ID27600A (fr)
IL (1) IL139787A0 (fr)
MX (1) MXPA00011889A (fr)
NO (1) NO325233B1 (fr)
NZ (1) NZ508314A (fr)
OA (1) OA12147A (fr)
PL (1) PL204628B1 (fr)
TR (1) TR200003513T2 (fr)
TW (1) TWI242435B (fr)
WO (1) WO1999062518A1 (fr)
YU (1) YU76100A (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
EP1577816A3 (fr) * 1996-09-04 2006-08-02 Intertrust Technologies Corp. Systèmes de support d'infrastructure de confiance, méthodes et techniques pour le commerce électronique sécurisé et la gestion de droits
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
HUP0103836A3 (en) * 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
KR100840727B1 (ko) * 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7189717B2 (en) * 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
WO2002006242A2 (fr) 2000-07-18 2002-01-24 Neurogen Corporation 2-aryl-4-pyrimidinones 5-substituees
EP1698627A1 (fr) * 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Composés de pyrazole comme inhibiteurs de la protéine kinase
ZA200301701B (en) * 2000-09-15 2004-03-01 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
AP2003002762A0 (en) 2000-09-15 2003-03-31 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
UA74228C2 (uk) * 2000-12-01 2005-11-15 Осі Фармасьютікалз, Інк. ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ, СПЕЦИФІЧНІ ДО АДЕНОЗИНОВОГО A<sub>1</sub>, A<sub>2А</sub> І A<sub>3</sub> РЕЦЕПТОРА, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
BR0115847A (pt) * 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
AU2002255452B2 (en) 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
EP1467995B1 (fr) * 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Composes d'antagonistes selectifs de pyrrolopyrimidine a2b ,leur synthese et leur utilisation
US20030229067A1 (en) * 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
ATE458483T1 (de) 2001-12-20 2010-03-15 Osi Pharm Inc Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
SI1483247T1 (sl) 2002-03-13 2009-12-31 Euro Celtique Sa Arilno substituirani pirimidini in njihova uporaba
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004013140A1 (fr) 2002-08-02 2004-02-12 Vertex Pharmaceuticals Incorporated Compositions pyrazole convenant comme inhibiteurs de gsk-3
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092170A2 (fr) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines et pyrazolotriazines et leurs procedes de fabrication et d'utilisation
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
WO2006028618A1 (fr) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (fr) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation Analogues de 2-polycyclique propynyle adenosine presentant une activite agoniste de a2a
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006087371A1 (fr) * 2005-02-18 2006-08-24 Solvay Pharmaceuticals Gmbh Compositions pharmaceutiques comprenant des inhibiteurs de l'endopeptidase neutre (epn), des inhibiteurs du systeme de production de l’endotheline endogene ainsi que des diuretiques
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
CN101316843B (zh) 2005-11-03 2013-01-02 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
US7763612B2 (en) * 2006-01-03 2010-07-27 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
CA2685876A1 (fr) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles et pyrazoles qui s'utilisent comme inhibiteurs de kinase
MX2010001137A (es) 2007-07-31 2010-03-31 Vertex Pharma Procesopara preparar 5-fluoro-1h-pirazol[3,4-b]piridin-3-amina y derivados del mismo.
WO2009046448A1 (fr) 2007-10-04 2009-04-09 Intellikine, Inc. Entités chimiques et leurs utilisations thérapeutiques
WO2009114874A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés
WO2009114870A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases, et procédés d’utilisation associés
WO2009153261A1 (fr) * 2008-06-18 2009-12-23 Solvay Pharmaceuticals Gmbh Dérivés de pyrrolo[2,3d]pyrimidine à substitution hydroxyphényle, procédés et produits intermédiares pour leur préparation et médicaments contenant ces composés
EP3009436B1 (fr) 2008-07-08 2019-06-05 Intellikine, LLC Inhibiteurs de kinases et procédés d'utilisation
JP2011529920A (ja) * 2008-07-31 2011-12-15 ジェネンテック， インコーポレイテッド ピリミジン化合物、組成物及び使用方法
WO2010027921A1 (fr) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-cristaux et formulations pharmaceutiques les comprenant
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
WO2010065743A2 (fr) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Composés bicycliques et leurs procédés de fabrication et d'utilisation
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
JP5572715B2 (ja) * 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｎ−７置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
CN102711766B (zh) * 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
CA2828483A1 (fr) 2011-02-23 2012-11-01 Intellikine, Llc Combinaison d'inhibiteurs des kinases et utilisations associees
JP2015522557A (ja) * 2012-06-07 2015-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト タンキラーゼのピロロピリミドン及びピロロピリドン阻害剤
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
CN110128316B (zh) * 2019-05-22 2021-08-31 北京大学深圳研究生院 5位取代的β-脯氨酸及其衍生物的制备方法
US12559745B2 (en) * 2020-11-23 2026-02-24 The Regents Of The University Of California Methods and compositions for linking RNA stem loops
CN113105469B (zh) * 2021-04-13 2022-04-22 中国科学院新疆理化技术研究所 一种三环呋喃并[2,3-d]嘧啶酮类化合物及用途
GEAP202516632A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB915303A (en) * 1958-03-13 1963-01-09 Wellcome Found Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof
US3910913A (en) 1969-11-04 1975-10-07 American Home Prod 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
DE3145287A1 (de) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4473571A (en) * 1983-01-17 1984-09-25 Sterling Drug Inc. 8-Substituted-2-(4-pyridinyl)-9H-purin-6-amines and their cardiotonic use
IN157280B (fr) 1983-07-15 1986-02-22 Hoechst India
GB8729994D0 (en) 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
IL89028A0 (en) 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
ATE140457T1 (de) * 1989-09-19 1996-08-15 Teijin Ltd Pyrrolo(2,3-d>pyrimidinderivate, verfahren zur herstellung und arzneimittelzusammensetzungen die diese enthalten
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5208240A (en) 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5516894A (en) 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
SK119194A3 (en) * 1992-04-03 1995-05-10 Upjohn Co Fharmaceuticaly active bicyclic-heterocyclic amines
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
JPH08512281A (ja) 1993-02-26 1996-12-24 メレル ダウ ファーマス−ティカルズ インコーポレイテッド アデノシンａ▲下１▼受容体拮抗剤としてのキサンチン誘導体類
JPH08511241A (ja) 1993-04-08 1996-11-26 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク ２−アミノイミダゾールとアルデヒドから４−および／または５−（ジ）置換された２−アミノイミダゾールを合成するための方法
WO1995011681A1 (fr) 1993-10-29 1995-05-04 Merck & Co., Inc. Antagonistes du recepteur de l'adenosine humaine
AU1867095A (en) 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JPH09508134A (ja) 1994-01-26 1997-08-19 チバ−ガイギー アクチェンゲゼルシャフト 変型オリゴヌクレオチド
US5646156A (en) 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
DK0783505T3 (da) * 1994-09-29 2001-07-02 Novartis Ag Pyrrolo[2,3-d]pyrimidiner og deres anvendelse
WO1996019478A1 (fr) 1994-12-19 1996-06-27 Novartis Ag Nucleosides carbocycliques substitues en position 6'
EP0729758A3 (fr) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5646130A (en) 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
CN1100778C (zh) 1995-07-06 2003-02-05 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US5780450A (en) 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997033879A1 (fr) 1996-03-15 1997-09-18 Merck & Co., Inc. Composes et methodes d'inhibition selective de l'activation du recepteur a3 de l'adenosine chez l'homme
JPH09291089A (ja) 1996-04-26 1997-11-11 Yamanouchi Pharmaceut Co Ltd 新規な５−チアゾリルウラシル誘導体又はその塩
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US5780481A (en) 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
CA2262421C (fr) 1996-08-23 2007-10-02 Novartis Ag Pyrrolopyrimidines substituees et procede pour leur preparation
WO1998008382A1 (fr) 1996-08-30 1998-03-05 Eli Lilly And Company Antifoliques non classiques de pyrrolo[2,3-d]pyrimidine
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
AU7890598A (en) * 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
FR2763334A1 (fr) 1997-05-13 1998-11-20 Lipha Derives anthraniliques
CA2295195C (fr) * 1997-06-18 2009-12-15 Aderis Pharmaceuticals, Inc. Compositions et procedes prevenant les restenoses consecutives a des interventions de revascularisation
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6151484A (en) 1997-08-08 2000-11-21 Ericsson Inc. Communications apparatus and methods for adaptive signal processing based on mobility characteristics
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
HUP0103836A3 (en) 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
US6878716B1 (en) * 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP2003522729A (ja) 1998-07-16 2003-07-29 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア 眼内圧の低下方法
US6463687B1 (en) * 1998-09-25 2002-10-15 Edward J. Dorstewitz Collapsible safety sign
US6158306A (en) 1998-10-06 2000-12-12 Gasparre; Pasquale Jar holder
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
KR100840727B1 (ko) 1999-12-02 2008-06-23 오에스아이 파마슈티컬스, 인코포레이티드 아데노신 ａ1, ａ2ａ 및 ａ3 수용체 특이 화합물 및 그의 사용방법
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6628342B2 (en) 2000-01-05 2003-09-30 Matsushita Electric Industrial Co., Ltd. Video signal processing apparatus
JP3317948B2 (ja) 2000-01-20 2002-08-26 エヌイーシーマイクロシステム株式会社 半導体集積回路のレイアウト設計方法及び半導体集積回路
US6465456B2 (en) 2000-06-29 2002-10-15 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
BR0115847A (pt) 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE60234118D1 (de) 2001-11-30 2009-12-03 Osi Pharm Inc Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
EP1467995B1 (fr) 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Composes d'antagonistes selectifs de pyrrolopyrimidine a2b ,leur synthese et leur utilisation
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
ATE458483T1 (de) 2001-12-20 2010-03-15 Osi Pharm Inc Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006518390A (ja) 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
JP6297783B2 (ja) 2013-03-08 2018-03-20 住友電気工業株式会社 炭化珪素半導体装置およびその製造方法
CN103309150B (zh) 2013-06-26 2015-06-17 上海华力微电子有限公司 版图数据的处理方法
KR102109129B1 (ko) 2013-07-02 2020-05-08 삼성전자주식회사 반사형 포토마스크 블랭크 및 반사형 포토마스크
JP6502627B2 (ja) 2014-07-29 2019-04-17 太陽誘電株式会社 コイル部品及び電子機器
CN106531794B (zh) 2015-09-15 2021-02-09 联华电子股份有限公司 高压金属氧化物半导体晶体管元件及其制造方法

Also Published As

Publication number Publication date
US7429574B2 (en) 2008-09-30
KR100722194B1 (ko) 2007-05-29
AU763658B2 (en) 2003-07-31
US6800633B2 (en) 2004-10-05
EP2011499A3 (fr) 2010-10-20
PL204628B1 (pl) 2010-01-29
NO20006090D0 (no) 2000-11-30
HUP0103836A3 (en) 2003-05-28
NZ508314A (en) 2004-03-26
PL347020A1 (en) 2002-03-11
TR200003513T2 (tr) 2001-06-21
ID27600A (id) 2001-04-12
AU4226599A (en) 1999-12-20
AP1411A (en) 2005-05-10
HUP0103836A2 (hu) 2002-02-28
BR9911612A (pt) 2001-02-06
TWI242435B (en) 2005-11-01
WO1999062518A1 (fr) 1999-12-09
US20020028782A1 (en) 2002-03-07
NO325233B1 (no) 2008-03-03
YU76100A (sh) 2003-12-31
EA200001245A1 (ru) 2001-08-27
EP1082120A1 (fr) 2001-03-14
AR020590A1 (es) 2002-05-22
MXPA00011889A (es) 2003-04-25
EP2011499A2 (fr) 2009-01-07
CN1311680A (zh) 2001-09-05
CN100528874C (zh) 2009-08-19
CZ302486B6 (cs) 2011-06-15
KR20010083042A (ko) 2001-08-31
AP2000002015A0 (en) 2000-12-31
OA12147A (en) 2006-05-05
CA2334200C (fr) 2011-01-25
JP4611524B2 (ja) 2011-01-12
US20090082369A1 (en) 2009-03-26
IL139787A0 (en) 2002-02-10
NO20006090L (no) 2001-01-31
CA2334200A1 (fr) 1999-12-09
CZ20004443A3 (cs) 2002-03-13
US20050043332A1 (en) 2005-02-24
JP2002516861A (ja) 2002-06-11
EA003604B1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
DZ2805A1 (fr) Composition à pyrroloÄ2,,3dÜ pyrimidine et leurs usages.
PT1225874E (pt) Composicoes antivirais.
TR199800375A3 (tr) Selant kompozisyonlari.
DZ2739A1 (fr) Composition de polyéthylène.
ITTO20000976A0 (it) Composizioni acaricide.
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
ID24703A (id) Kuinolon antimikroba, komposisi dan penggunaannya
IT1308627B1 (it) Composizioni fluoroelastomeriche.
IT1308628B1 (it) Composizioni fluoroelastomeriche.
DE69912141D1 (de) Härtbare perfluorelastomerzusammensetzung
TR199901077A3 (tr) Ispençiyari formülasyonlar.
BR9915457B1 (pt) composições de moldagem, uso e artigo.
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
ID28694A (id) Komposisi sampo
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
DE69918698D1 (de) Härtbare perfluorelastomerzusammensetzung
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
EE200200275A (et) Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
DE69928862D1 (de) Zusammensetzung
DE69942892D1 (de) Gaserzeugende zusammensetzung
NO20010873L (no) Mikropartikkel-blanding
FR2781481B1 (fr) Nouveaux 2-amino, 4-alkylamino pyrimidine 3-oxydes et composition les comprenant
NO20012727L (no) 3,4,5-trisubstituerte arylnitronforbindelser og farmasöytiske sammensetninger som inneholder samme
ZA993883B (en) Adhesive compositions.
TR199901017A3 (tr) Böcek ilaci terkibi.